May 23, 2018
Bayer Presents Preliminary Insights from Global Patient Survey at World Federation of Hemophilia 2018 World Congress
May 22, 2018
BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress
May 17, 2018
BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress
Mar 28, 2018
Rare Hemophilia Factors Market Size Worth $336.3 Million by 2025: Grand View Research, Inc.
Jan 09, 2018
rHEALTH Achieves CE Mark for its Factor VIII Test Kit
Dec 11, 2017
BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting
Dec 09, 2017
BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication
Dec 06, 2017
BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition
Dec 01, 2017
Asia-Pacific $1.49 Billion Hemophilia A and B Therapeutics Market to 2023
Nov 22, 2017
US Hemostasis Diagnostics Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
Nov 22, 2017
US Coagulation Testing Market 2021: Growth Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
Nov 22, 2017
UK Coagulation Testing Market 2021: Growth Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
Nov 16, 2017
FDA approves new treatment to prevent bleeding in certain patients with hemophilia A
Nov 08, 2017
Overall world revenue for Bleeding Disorder Treatment will surpass $6bn in 2017
Sep 28, 2017
Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment